ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
This is a prospective cohort study to observe the efficacy and safety of Tofacitinib in children with Blau syndrome (BS). The investigators would analyze the rate of remission or low disease activity after treatment as well as changes in inflammatory markers, patients' and physician's global assessment of disease activity to determine the efficacy and safety of Tofacitinib.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis#885597
- TES for the Treatment of RP#1058005
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy#891131
- Comparative Effectiveness and Tolerance of Subliminal Subthreshold Transscleral Cyclophotocoagulation#897153
- The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis#883509
Record · ID 863956
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive